Amcinonide

Summary

Amcinonide (CHEMBL1200732) is an approved small-molecule anti-inflammatory drug (ATC D07AC11).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D07AC11
• Chemistry: 502.6 Da · C28H35FO7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200732
Name	Amcinonide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	443958
ChEBI	CHEBI:31199
ATC	D07AC11
Molecular formula	C28H35FO7
Molecular weight	502.6
InChIKey	ILKJAFIWWBXGDU-MOGDOJJUSA-N

SMILES: CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3CCC5=CC(=O)C=C[C@@]54C)F)O)C)OC6(O2)CCCC6

IUPAC name: [2-[(1S,2S,4R,8S,9S,11S,12R,13S)-12-fluoro-11-hydroxy-9,13-dimethyl-16-oxospiro[5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-diene-6,1’-cyclopentane]-8-yl]-2-oxoethyl] acetate

Pharmacological roles (ChEBI): anti-inflammatory drug.

Also known as: Amcinonida, Amcinonide, CL 34699, CL-34699, Cyclocort, NSC-758620, SID855515, AMCINONIDE, SID56423154, amcinonide, SID144204964

Patent coverage: 4,448 distinct patent families (16,116 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Nuclear receptor ROR-gamma, Glucocorticoid receptor, Progesterone receptor, Cannabinoid receptor 1, Voltage-gated inwardly rectifying potassium channel KCNH2, Cruzipain, Hypoxia-inducible factor 1-alpha, Neuropeptide S receptor.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HIF1A	8.89	Potency	1.3	nM	CHEMBL_ACT_4117748
HIF1A	8.89	Potency	1.3	nM	CHEMBL_ACT_4519799
NR3C1	7.8	AC50	16	nM	CHEMBL_ACT_25176116
PGR	6.67	AC50	212	nM	CHEMBL_ACT_25223265
NPSR1	5.4	Potency	3981	nM	CHEMBL_ACT_4909145
CNR1	5.37	AC50	4247	nM	CHEMBL_ACT_25181797
P51450	5.05	Potency	8912	nM	CHEMBL_ACT_4762140

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).